Daman Investments seeks Dubai listing via IPO early next year



Daman Investments, a Dubai- based finance house, is to seek a stock market listing via an initial public offering in the first quarter of next year.

Shehab Gargash, the chairman and founder of Daman, said that some 55 per cent of the company would be floated on the Dubai Financial Market (DFM), once approval had been obtained from the regulator, the Securities and Commodities Authority (SCA).

He declined to estimate the valuation of the IPO, which is being discussed with the regulator. But he said that none of the existing shareholders would sell down their holdings in the flotation.

“The funds raised will be used to scale up our existing businesses and invest in various opportunities in the UAE and wider region,” he said.

The Daman IPO is the latest in a series of public offerings on the DFM, where there have been successful debuts from Emaar Malls and Marka, while Amanat, a “greenfield” health and education company, is in the final stages of subscription.

Yesterday’s intention to float is the fruition of a long-standing ambition by the group, which was delayed by the onset of the global financial crisis in 2009. “This is the culmination of many years of hard work. Our listing will help broaden and deepen the UAE market for investors, and I expect more of the same in the coming months,” Mr Gargash said.

He added that he would welcome international interest in the shares, explaining that there had been significant interest in the company during a recent roadshow by the DFM in New York.

“There are a lot of banks in the UAE listed, but there had been a dearth in financial services,” he said. Daman’s business involves brokerage and asset management, venture capital, private equity and corporate advisory services.

In its annual review of investment prospects, Daman was overwhelmingly bullish in its outlook for the immediate future. “We think that valuation metrics in UAE bourses still look attractive until the end of the first quarter 2015, given the expected growth potential of the companies’ bottom lines,” the review said.

The review said that “measures undertaken for healthy real estate growth” had reduced the potential for a property “bubble”, and that IPO activity would continue. But the review warned about the risk of lack of liquidity in local makers over the longer term.

“Beyond Q1 2015 the outlook becomes ambiguous at best, given the increase in capital market activity in the form of IPOs,” the review said.

fkane@thenational.ae

Follow The National's Business section on Twitter

Awar Qalb

Director: Jamal Salem

Starring: Abdulla Zaid, Joma Ali, Neven Madi and Khadija Sleiman

Two stars

Where to buy and try:

Nutritional yeast

DesertCart

Organic Foods & Café

Bulletproof coffee

Wild & The Moon

Amasake

Comptoir 102

DesertCart

Organic Foods & Café

Charcoal drinks and dishes

Various juice bars, including Comptoir 102

Bridgewater Tavern

3 Fils

Jackfruit

Supermarkets across the UAE

Who are the Sacklers?

The Sackler family is a transatlantic dynasty that owns Purdue Pharma, which manufactures and markets OxyContin, one of the drugs at the centre of America's opioids crisis. The family is well known for their generous philanthropy towards the world's top cultural institutions, including Guggenheim Museum, the National Portrait Gallery, Tate in Britain, Yale University and the Serpentine Gallery, to name a few. Two branches of the family control Purdue Pharma.

Isaac Sackler and Sophie Greenberg were Jewish immigrants who arrived in New York before the First World War. They had three sons. The first, Arthur, died before OxyContin was invented. The second, Mortimer, who died aged 93 in 2010, was a former chief executive of Purdue Pharma. The third, Raymond, died aged 97 in 2017 and was also a former chief executive of Purdue Pharma. 

It was Arthur, a psychiatrist and pharmaceutical marketeer, who started the family business dynasty. He and his brothers bought a small company called Purdue Frederick; among their first products were laxatives and prescription earwax remover.

Arthur's branch of the family has not been involved in Purdue for many years and his daughter, Elizabeth, has spoken out against it, saying the company's role in America's drugs crisis is "morally abhorrent".

The lawsuits that were brought by the attorneys general of New York and Massachussetts named eight Sacklers. This includes Kathe, Mortimer, Richard, Jonathan and Ilene Sackler Lefcourt, who are all the children of either Mortimer or Raymond. Then there's Theresa Sackler, who is Mortimer senior's widow; Beverly, Raymond's widow; and David Sackler, Raymond's grandson.

Members of the Sackler family are rarely seen in public.


Energy This Week

Expert analysis on oil & gas renewables and clean energy

      By signing up, I agree to The National's privacy policy
      Energy This Week